Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15552555 | 0.94 | MEN1 (0.60) | MEN1KMT2AEPHX1ACP3PPARA | |
| SCHEMBL22394811 | 0.90 | MEN1 (0.56) | MEN1KMT2AEPHX1P4HTMPPARA | |
| SCHEMBL9109356 | 0.88 | MEN1 (0.55) | MEN1KMT2AITGB1ITGA4CYP1A2 | |
| SCHEMBL9109693 | 0.88 | MEN1 (0.55) | MEN1KMT2APPARAITGB1ITGA4 | |
| SCHEMBL28605536 | 0.88 | EPHX1 (0.71) | MEN1KMT2AEPHX1ACP3TP53 | |
| SCHEMBL29610281 | 0.88 | EPHX1 (0.71) | MEN1KMT2AEPHX1ACP3TP53 | |
| SCHEMBL9110049 | 0.87 | MEN1 (0.53) | MEN1KMT2AACP3ADRB3CCKAR | |
| SCHEMBL27923790 | 0.85 | MEN1 (0.55) | MEN1KMT2AACP3PPARAPPARG | |
| SCHEMBL15058103 | 0.84 | MEN1 (0.61) | MEN1KMT2AACP3PPARATP53 | |
| SCHEMBL6366829 | 0.83 | MEN1 (0.67) | MEN1KMT2AACP3LMNACCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646027-B1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8697733-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130338195-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. | 2013-12-19 | — | — | US | disclosed |
| US-8492410-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130150411-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8399492-B2 | Pyridine derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120142736-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-5599966-A | SUITABLE FOR TREATMENT OF DISEASES OF RESPIRATORY PASSAGES | BYK NEDERLAND BV (NL) | 1997-02-04 | — | — | US | disclosed |
| EP-0664788-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | Byk Nederland BV (NL) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994008945-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | BYK NEDERLAND BV (NL) | 1994-04-28 | — | — | WO | disclosed |
| CN-1015622-B | Hydrogenated cinnamic acid derivative and its method for making | HOFFMANN LA ROCHE (CH) | 1992-02-26 | — | — | CN | disclosed |
| CN-1036952-A | Hydrogenated cinnamic acid derivative and its method for making | HOFFMANN LA ROCHE (CH) | 1989-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150411-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MEN1 3719/4885KMT2A 4068/4885EPHX1 1412/4885 |
| US-20130338195-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MEN1 3719/4885KMT2A 4068/4885EPHX1 1412/4885 |
| US-20120142736-A1 | NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | MEN1 3719/4885KMT2A 4068/4885EPHX1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.